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Introduction: Serum tryptase quantitation is used as a marker of mast cell activation. Levels are elevated in allergic (anaphylactic) reactions, but can also be chronically high in conditions such as mastocytosis and haematological neoplasms. Blood samples for measurement of tryptase levels in the assessment of allergic conditions are optimally obtained 15 min to 3 h after symptom onset. Serial measurement of tryptase levels and measurement of a baseline level after recovery are reported to be more useful than measurement at only one point in time in this assessment.
In all routine clinical laboratories enrolled in the RCPAQAP Tryptase Program levels of serum tryptase are measured using the Thermo Fisher ImmunoCAP systems. Considering this, there should be limited methodological variation in results obtained across laboratories.
Methods: A retrospective review of results from January 2014 to June 2017 from the Royal College of Pathologists of Australasia Quality Assurance Programs (RCPAQAP) tryptase module was undertaken. Average inter laboratory coefficient of variation (CV%) over a range of serum tryptase levels were reviewed.
Results: Twenty-eight samples were analysed, with 20-27 results submitted for each sample. Mean serum tryptase values ranged from 3.3 to 127 μg/L. The average CV% of all samples was 8% (range 4.4-12.7%). Good inter laboratory variation was seen at all levels.
Conclusion:
The inter laboratory CV% of serum tryptase as measured on the ImmunoCAP system shows good reproducibility across a range of levels. Andrographis paniculata (A. paniculata) is a plant that has been in use for centuries in Southeast Asia as a traditional herbal medicine. Andrographolide, a labdane diterpenoid lactone, was first reported in 1951 as the bioactive constituent. A. paniculata has been studied for its anti-inflammatory properties and more recently marketed in herbal supplementary medications for the treatment of common upper respiratory tract infections.
Although cases of hypersensitivity reactions to A. paniculata have been described in literature, evidence supporting a direct causation is currently lacking. To date, there is no validated allergy testing method for A. paniculata, and the risk of cross reactivity to other analogues is also unknown.
We present two patients who had episodes of anaphylaxis after ingestion of A. paniculata containing supplements. Patient A took two different supplements 6 months apart, Good health's Viralex Attack and Blackmores Immunoshield respectively, and both times experienced immediate Ig-E mediated symptoms with the second episode resulting in anaphylaxis. Patient B took Good health's Viralex Attack and developed anaphylaxis. Both patients received intramuscular adrenaline injection and were admitted to hospital for observation.
The Therapeutic Goods Administration in Australia issued a safety review in 2015 after receiving 43 reports of anaphylaxis to products containing A. paniculata between 2002 and 2014. Three out of four cases of adverse reactions to A. paniculata reported to the Centre of Adverse Reactions Monitoring in New Zealand in the last year were anaphylaxis. Medsafe New Zealand issued a warning in March 2017 and A. paniculata has since been removed from some products.
In conclusion, clinicians should be aware of A. paniculata as a potential significant allergen and suspect it as a possible culprit in patients presenting with anaphylaxis or other allergic reactions following ingestion of a natural health product. Furthermore, we discuss the options and limitations of tests available to the allergist for novel allergens. Background: Recognition and Management of Anaphylaxis Program (RAMOAP) is a scenario-based training course designed to train first aid trainers and teachers to deliver face-to-face recognition and management of anaphylaxis education to school staff in the school setting. The NSW Anaphylaxis Education Program (NSWAEP) has previously reported that our RAMOAP train-the-trainer course increased anaphylaxis knowledge of registered first aid trainers and resulted in high levels of anaphylaxis knowledge at the conclusion of the course.
P3 DIFFERENCES IN KNOWLEDGE BETWEEN SCHOOL TEACHERS AND REGISTERED FIRST AID TRAINERS UNDERGOING TRAINING TO DELIVER SCHOOL-BASED ANAPHYLAXIS EDUCATION
Aim: To evaluate knowledge of recognition and management of anaphylaxis in school teachers prior to and after completing the RAMOAP training program and to compare this with the same data collected from first aid trainers.
Method: From November 2016 to June 2017 inclusive all school teachers who undertook the RAMOAP train-the-trainer session undertook a 30-question multiple choice test at the beginning and end of the training day. The test included theoretical material from pre requisite e-lessons. Median scores were calculated for participants who sat both the pre-and post-test. The results were compared by two-tailed Wilcoxon test. The pre-and post-training knowledge of this group was compared with that of a group of first aid trainers by Mann-Whitney test.
Results: 156 school teachers undertook the pre and post-test over the study period. Knowledge was higher following the training course (P < 0.05, median score difference = 4, IQR = 3-6) with pre-test median score of 25 (IQR = 23-26) compared with post-test median score of 29 . Compared with the group of 115 first aid trainers, teachers were more knowledgeable both before (pre-test median score 25 vs 23: P < 0.05) and after (post-test mean score 29 vs 28: P < 0.05) training.
Conclusion: NSWAEP's RAMOAP train-the-trainer session was effective at increasing teachers' anaphylaxis knowledge, and resulted in a high level of anaphylaxis knowledge at the conclusion of the course. Teachers' anaphylaxis knowledge was greater than first aid trainers' before training, and training reduced but did not fully remove this difference, with teachers scoring higher than first aid trainers at both time points. A 47-year-old lady was admitted for management of frequent, generalised idiopathic anaphylaxis. The patient was brought to hospital by ambulance, unconscious with hypotensive anaphylaxis. She required an adrenaline infusion and had a mast cell tryptase rise to 27.9 mcg/L. Nine further episodes of anaphylaxis were witnessed in hospital, initially occurring every other day, with one intensive care admission.
P4 ANAPHYLACTIC STORM: A MULTIDISCIPLINARY TREATMENT APPROACH
The patient had a background of recurrent idiopathic anaphylaxis with six episodes since 2007. Episodes were characterised by itch, throat tightness, breathlessness, wheeze, bowel urgency, and on some occasions, syncope. Baseline mast cell tryptase was normal, with rises within the normal range following some episodes. She also had bee venom anaphylaxis. Attempts 
